ATE536363T1 - Verfahren zur herstellung von mischungen von trifluoroacetyl-glatirameracetat bei verwendung von hydrobromsäure - Google Patents

Verfahren zur herstellung von mischungen von trifluoroacetyl-glatirameracetat bei verwendung von hydrobromsäure

Info

Publication number: ATE536363T1
Authority: AT; Austria
Prior art keywords: trifluoroacetyl; hydrobromic acid; glatiramer acetate; producing mixtures; tyrosine
Prior art date: 2004-09-09

Application number

AT10150124T

Other languages

English (en)

Inventor

Ben-Zion Dolitzky

Original Assignee

Teva Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-09

Filing date

2005-09-09

Publication date

2011-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36037047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE536363(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-09-09 Application filed by Teva Pharma filed Critical Teva Pharma

2011-12-15 Application granted granted Critical

2011-12-15 Publication of ATE536363T1 publication Critical patent/ATE536363T1/de

Links

239000000203 mixture Substances 0.000 title abstract 3
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 title 1
229960003776 glatiramer acetate Drugs 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
229920001184 polypeptide Polymers 0.000 abstract 3
102000004196 processed proteins & peptides Human genes 0.000 abstract 3
108090000765 processed proteins & peptides Proteins 0.000 abstract 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
239000004472 Lysine Substances 0.000 abstract 1
235000004279 alanine Nutrition 0.000 abstract 1
150000001413 amino acids Chemical group 0.000 abstract 1
235000013922 glutamic acid Nutrition 0.000 abstract 1
239000004220 glutamic acid Substances 0.000 abstract 1
239000012535 impurity Substances 0.000 abstract 1
235000018977 lysine Nutrition 0.000 abstract 1
229910021645 metal ion Inorganic materials 0.000 abstract 1
235000002374 tyrosine Nutrition 0.000 abstract 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
150000003668 tyrosines Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Diabetes (AREA)
Zoology (AREA)
Toxicology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Rheumatology (AREA)
Rehabilitation Therapy (AREA)
Transplantation (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT10150124T 2004-09-09 2005-09-09 Verfahren zur herstellung von mischungen von trifluoroacetyl-glatirameracetat bei verwendung von hydrobromsäure ATE536363T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US60884304P	2004-09-09	2004-09-09

Publications (1)

Publication Number	Publication Date
ATE536363T1 true ATE536363T1 (de)	2011-12-15

Family

ID=36037047

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT10150124T ATE536363T1 (de)	2004-09-09	2005-09-09	Verfahren zur herstellung von mischungen von trifluoroacetyl-glatirameracetat bei verwendung von hydrobromsäure
AT05791236T ATE454396T1 (de)	2004-09-09	2005-09-09	Verfahren zur herstellung von polypeptidmischungen unter anwendung von aufgereinigter bromwasserstoffsäure

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT05791236T ATE454396T1 (de)	2004-09-09	2005-09-09	Verfahren zur herstellung von polypeptidmischungen unter anwendung von aufgereinigter bromwasserstoffsäure

Country Status (27)

Country	Link
US (2)	US7495072B2 (de)
EP (3)	EP2361924B1 (de)
JP (1)	JP5149008B2 (de)
KR (1)	KR101317131B1 (de)
CN (1)	CN101166754B (de)
AT (2)	ATE536363T1 (de)
AU (1)	AU2005282249B2 (de)
BR (1)	BRPI0515033B1 (de)
CA (1)	CA2579656C (de)
CY (1)	CY1110280T1 (de)
DE (1)	DE602005018800D1 (de)
DK (3)	DK2177528T3 (de)
ES (3)	ES2382298T3 (de)
HR (3)	HRP20100164T1 (de)
IL (2)	IL181596A (de)
IS (1)	IS8622A (de)
MX (1)	MX2007002760A (de)
NO (1)	NO20071632L (de)
NZ (1)	NZ554018A (de)
PL (3)	PL1799703T3 (de)
PT (3)	PT1799703E (de)
RS (3)	RS52265B (de)
RU (1)	RU2388764C2 (de)
SI (3)	SI1799703T1 (de)
UA (1)	UA91029C2 (de)
WO (1)	WO2006029393A2 (de)
ZA (1)	ZA200702591B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2527760T3 (es) *	1998-07-23	2015-01-29	Yeda Research And Development Co., Ltd.	Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
IL141021A0 (en)	1998-07-23	2002-02-10	Yeda Res & Dev	Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6800287B2 (en)	1998-09-25	2004-10-05	Yeda Research And Development Co., Ltd.	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2002076503A1 (en) *	2000-06-20	2002-10-03	Mayo Foundation For Medical Education And Research	Treatment of central nervous system diseases by antibodies against glatiramer acetate
US7429374B2 (en) *	2001-12-04	2008-09-30	Teva Pharmaceutical Industries, Ltd.	Process for the measurement of the potency of glatiramer acetate
EP1778286A4 (de) *	2004-03-03	2009-04-08	Teva Pharma	Kombinationstherapie mit glatiramer-acetat und riluzol
ZA200702591B (en) *	2004-09-09	2009-03-25	Teva Pharma	Process for preparation of mixtures of polypeptides using purified hydrobromic acid
HRP20160455T1 (hr) *	2004-09-09	2016-07-15	Yeda Research And Development Co., Ltd.	Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
US8324641B2 (en) *	2007-06-29	2012-12-04	Ledengin, Inc.	Matrix material including an embedded dispersion of beads for a light-emitting device
AR052321A1 (es) *	2004-10-29	2007-03-14	Sandoz Ag	Procesos para la preparacion de un polipeptido
JP2008528589A (ja) *	2005-02-02	2008-07-31	テバファーマシューティカルインダストリーズリミティド	水素化分解を用いてポリペプチド混合物を作成する方法
WO2006089164A1 (en) *	2005-02-17	2006-08-24	Teva Pharmaceutical Industries, Ltd.	Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
CA2606194A1 (en) *	2005-04-25	2006-11-02	Yeda Research And Development Company	Markers associated with the therapeutic efficacy of glatiramer acetate
WO2009017775A2 (en) *	2007-08-02	2009-02-05	Scinopharm Taiwan Ltd.	Process for the preparation of a polypeptide
CA2702437C (en) *	2007-11-28	2013-06-25	Teva Pharmaceutical Industries Ltd.	Method of delaying the onset of clinically definite multiple sclerosis
ES2449865T5 (es)	2008-04-16	2022-11-18	Momenta Pharmaceuticals Inc	Análisis de composiciones de copolímeros de aminoácidos
KR20110059606A (ko) *	2008-08-07	2011-06-02	시노팜 타이완 리미티드	글라티라머 아세테이트의 합성
US8399600B2 (en) *	2008-08-07	2013-03-19	Sigma-Aldrich Co. Llc	Preparation of low molecular weight polylysine and polyornithine in high yield
RU2011144566A (ru)	2009-04-03	2013-05-10	Момента Фармасьютикалз, Инк.	Контроль сополимерных композиций
NZ598661A (en)	2009-08-20	2013-02-22	Yeda Res & Dev	Low frequency glatiramer acetate therapy
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) *	2010-03-16	2014-06-24	Teva Pharmaceutical Industries, Ltd.	Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
JP2013529194A (ja) *	2010-04-27	2013-07-18	ドクターレディズラボラトリーズリミテッド	ポリペプチドおよびその塩の調製
CA2814500A1 (en)	2010-10-11	2012-04-19	Teva Pharmaceutical Industries Ltd	Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
US8788046B2 (en)	2010-11-11	2014-07-22	Spr Therapeutics, Llc	Systems and methods for the treatment of pain through neural fiber stimulation
CA2827275A1 (en) *	2011-02-14	2012-09-20	Usv Limited	Copolymer-1, process for preparation and analytical methods thereof
JP5701103B2 (ja) *	2011-03-02	2015-04-15	昭和シェル石油株式会社	潤滑油のための消泡剤組成物及びそれを用いた消泡方法
WO2012143924A1 (en)	2011-04-21	2012-10-26	Mapi Pharma Ltd.	Random pentapolymer for treatment of autoimmune diseases
WO2013009885A2 (en)	2011-07-11	2013-01-17	Momenta Pharmaceuticals, Inc.	Evaluation of copolymer diethylamide
WO2013009864A1 (en)	2011-07-11	2013-01-17	Momenta Pharmaceuticals, Inc.	Structure assessment of heterogeneous polypeptide mixtures
US8575198B1 (en)	2011-09-07	2013-11-05	Momenta Pharmaceuticals, Inc.	In-process control for the manufacture of glatiramer acetate
HK1200274A1 (en)	2011-10-10	2015-08-07	Teva Pharmaceutical Industries Ltd.	Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
CN102717992A (zh) *	2012-05-30	2012-10-10	苏州市旭洋工业搪瓷厂	一种搪玻璃溴素贮罐
CN102718963B (zh) *	2012-06-19	2014-10-15	深圳翰宇药业股份有限公司	聚合物多肽的制备方法
HK1213830A1 (zh)	2012-10-10	2016-07-15	Teva Pharmaceutical Industries Ltd.	用於预测醋酸格拉替雷临床反应的生物标志物
UY35790A (es)	2013-10-21	2015-05-29	Teva Pharma	Marcadores genéticos que predicen la respuesta al acetato de glatiramer
WO2015066515A1 (en)	2013-11-01	2015-05-07	Receptos, Inc.	Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
CN104844697B (zh) *	2014-09-26	2018-10-23	深圳翰宇药业股份有限公司	醋酸格拉替雷的制备方法
US9155775B1 (en)	2015-01-28	2015-10-13	Teva Pharmaceutical Industries, Ltd.	Process for manufacturing glatiramer acetate product
US12097292B2 (en)	2016-08-28	2024-09-24	Mapi Pharma Ltd.	Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh)	2016-08-31	2019-07-05	Mapi医药公司	包含醋酸格拉替雷的储库系统
CN110382052A (zh)	2017-03-26	2019-10-25	Mapi医药公司	用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
US20190202984A1 (en) *	2018-01-03	2019-07-04	Kinbio Ltd.	Process of preparing glatiramer acetate

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3846550A (en) *	1971-01-21	1974-11-05	H Akrongold	Cosmetic skin powder containing urea
IL36670A (en) *	1971-04-21	1974-09-10	Sela M	Therapeutic basic copolymers of amino acids
JPS54119499A (en) *	1978-03-09	1979-09-17	Shionogi & Co Ltd	Triazolobenzodiazepin derivative
JPS6053535A (ja) *	1983-09-02	1985-03-27	Nitto Boseki Co Ltd	規則性ポリアミノ酸樹脂の製造方法
SU1182051A1 (ru)	1984-04-28	1985-09-30	Таджикский государственный университет им.В.И.Ленина	Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина
DE3684333D1 (de)	1985-06-18	1992-04-16	Univ Emory	Biologisch wirksame kopolymere.
DD257174A3 (de)	1985-12-20	1988-06-08	Ve Forschungszentrum Biotechno	Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease
SU1469826A1 (ru)	1986-05-30	1995-11-20	Институт Высокомолекулярных Соединений Ан Ссср	Сополимер l-лизина с l-глутаминовой кислотой, содержащий дофаминовые боковые группы, обладающий пролонгированной гипотензивной активностью и компенсаторным эффектом при геморрагическом шоке, и способ его получения
SU1690368A1 (ru)	1989-07-20	1995-08-20	Институт Высокомолекулярных Соединений Ан Ссср	Статистические сополимеры в качестве низкотоксичных веществ, обладающих пролонгированным гипотензивным действием, и способ их получения
DE3930733A1 (de)	1989-09-14	1991-03-28	Roehm Gmbh	Verfahren zur herstellung eines komplexierten arzneimittels
USH1312H (en) *	1992-05-28	1994-05-03	Cytogen Corporation	Method for the preparation of gyk-dtpa
RU2198900C2 (ru) *	1994-05-24	2003-02-20	Еда Рисерч энд Дивелопмент Ко., Лтд.	Усовершенствованный сополимер-1 и способ его получения
IL113812A (en) *	1994-05-24	2000-06-29	Yeda Res & Dev	Copolymer-1 pharmaceutical compositions containing it and its use
US5858964A (en) *	1995-04-14	1999-01-12	Yeda Research And Development Co. Ltd.	Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
FR2750423B1 (fr)	1996-06-28	1998-08-14	Rhone Poulenc Chimie	Procede d'hydrogenation asymetrique d'un compose cetonique
US6214791B1 (en) *	1997-01-10	2001-04-10	Yeda Research And Development Co. Ltd.	Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
KR20010015639A (ko)	1997-09-30	2001-02-26	스즈키 다다시	술포닐 유도체
US5872122A (en) *	1997-10-16	1999-02-16	Monsanto Company	Pyrimidinylamidino β-amino acid derivatives useful as inhibitors of platelet aggregation
US5965047A (en)	1997-10-24	1999-10-12	Steag Ast	Rapid thermal processing (RTP) system with rotating substrate
GB9724627D0 (en)	1997-11-20	1998-01-21	Genencor Int Bv	Gram positive microorganism formate pathway
IL141021A0 (en) *	1998-07-23	2002-02-10	Yeda Res & Dev	Treatment of autoimmune conditions with copolymer 1 and related copolymers
ES2527760T3 (es) *	1998-07-23	2015-01-29	Yeda Research And Development Co., Ltd.	Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) *	1998-09-25	2004-10-05	Yeda Research And Development Co., Ltd.	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en) *	1998-09-25	2003-02-04	Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
AU775073C (en)	1998-11-12	2007-05-03	Yeda Research And Development Co. Ltd.	Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
US6114649A (en)	1999-07-13	2000-09-05	Duran Technologies Inc.	Anode electrode for plasmatron structure
AU7343800A (en)	1999-09-03	2001-04-10	Quorum Sciences, Inc.	Quorum sensing signaling in bacteria
DE19944003C1 (de)	1999-09-14	2001-03-22	Baumeister & Ostler Gmbh Co	Faltbare Trenneinrichtung
JP4328050B2 (ja) *	2000-01-20	2009-09-09	イエダリサーチアンドデベロップメントカンパニーリミテッド	神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
IL150895A0 (en)	2000-02-18	2003-02-12	Teva Pharma	Oral, nasal and pulmonary formulations of copolymer-1
US7022663B2 (en) *	2000-02-18	2006-04-04	Yeda Research And Development Co., Ltd.	Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en)	2000-06-05	2002-06-20	Yong V. Wee	Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
EP1294390B1 (de)	2000-06-07	2006-01-04	YEDA RESEARCH AND DEVELOPMENT CO., Ltd.	Verwendung des copolymer-1 peptids sowie von damit verwandten peptiden und polypeptiden und von damit behandelten t-zellen zur neuroprotektion vor glutamattoxizitaet
WO2002076503A1 (en) *	2000-06-20	2002-10-03	Mayo Foundation For Medical Education And Research	Treatment of central nervous system diseases by antibodies against glatiramer acetate
JP3698984B2 (ja)	2000-11-10	2005-09-21	ヤマウチ株式会社	シュープレス用ベルト
MXPA03004458A (es) *	2000-11-20	2005-01-25	Pharmacia Corp	Arilpiridinas y heteroarilpiridinas sustituidas utiles para inhibicion selectiva de la cascada de coagulacion.
JP3661935B2 (ja)	2001-06-20	2005-06-22	ソニー株式会社	情報処理装置および方法、記録媒体、並びにプログラム
US7429374B2 (en) *	2001-12-04	2008-09-30	Teva Pharmaceutical Industries, Ltd.	Process for the measurement of the potency of glatiramer acetate
US7527981B2 (en)	2002-05-09	2009-05-05	Dennis Farwell	Bioweapon-detecting fibrous-network products and methods for making same
CA2411786C (en) *	2002-11-13	2009-01-27	Brantford Chemicals Inc.	A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
WO2004043995A2 (en)	2002-11-13	2004-05-27	Apotex Pharmachem Inc.	Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
DE10353960B4 (de)	2003-10-16	2006-03-23	Vertilas Gmbh	Oberflächenemittierender Halbleiterlaser mit strukturiertem Wellenleiter
HRP20160455T1 (hr) *	2004-09-09	2016-07-15	Yeda Research And Development Co., Ltd.	Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
ZA200702591B (en) *	2004-09-09	2009-03-25	Teva Pharma	Process for preparation of mixtures of polypeptides using purified hydrobromic acid
JP2008528589A (ja) *	2005-02-02	2008-07-31	テバファーマシューティカルインダストリーズリミティド	水素化分解を用いてポリペプチド混合物を作成する方法
CA2606194A1 (en) *	2005-04-25	2006-11-02	Yeda Research And Development Company	Markers associated with the therapeutic efficacy of glatiramer acetate
WO2007072865A1 (ja)	2005-12-22	2007-06-28	Pioneer Corporation	施設情報配信装置、通信端末、施設情報配信方法、情報出力方法、プログラム、および記録媒体

2005
- 2005-09-09 ZA ZA200702591A patent/ZA200702591B/xx unknown
- 2005-09-09 MX MX2007002760A patent/MX2007002760A/es active IP Right Grant
- 2005-09-09 DK DK10150124.5T patent/DK2177528T3/da active
- 2005-09-09 PL PL05791236T patent/PL1799703T3/pl unknown
- 2005-09-09 JP JP2007531423A patent/JP5149008B2/ja not_active Expired - Fee Related
- 2005-09-09 DE DE602005018800T patent/DE602005018800D1/de not_active Expired - Lifetime
- 2005-09-09 PL PL10194363T patent/PL2361924T3/pl unknown
- 2005-09-09 EP EP10194363.7A patent/EP2361924B1/de not_active Revoked
- 2005-09-09 PT PT05791236T patent/PT1799703E/pt unknown
- 2005-09-09 AT AT10150124T patent/ATE536363T1/de active
- 2005-09-09 AT AT05791236T patent/ATE454396T1/de active
- 2005-09-09 EP EP05791236A patent/EP1799703B1/de not_active Revoked
- 2005-09-09 DK DK05791236.2T patent/DK1799703T3/da active
- 2005-09-09 US US11/223,072 patent/US7495072B2/en not_active Expired - Lifetime
- 2005-09-09 SI SI200530934T patent/SI1799703T1/sl unknown
- 2005-09-09 NZ NZ554018A patent/NZ554018A/en not_active IP Right Cessation
- 2005-09-09 KR KR1020077007738A patent/KR101317131B1/ko not_active Expired - Lifetime
- 2005-09-09 PT PT101943637T patent/PT2361924E/pt unknown
- 2005-09-09 HR HR20100164T patent/HRP20100164T1/hr unknown
- 2005-09-09 RU RU2007112956/04A patent/RU2388764C2/ru active
- 2005-09-09 ES ES10150124T patent/ES2382298T3/es not_active Expired - Lifetime
- 2005-09-09 ES ES10194363.7T patent/ES2451006T3/es not_active Expired - Lifetime
- 2005-09-09 DK DK10194363.7T patent/DK2361924T3/en active
- 2005-09-09 RS RS20120091A patent/RS52265B/sr unknown
- 2005-09-09 EP EP10150124A patent/EP2177528B1/de not_active Revoked
- 2005-09-09 RS RSP-2010/0114A patent/RS51257B/sr unknown
- 2005-09-09 SI SI200531482T patent/SI2177528T1/sl unknown
- 2005-09-09 CN CN200580033851.5A patent/CN101166754B/zh not_active Expired - Lifetime
- 2005-09-09 ES ES05791236T patent/ES2338138T3/es not_active Expired - Lifetime
- 2005-09-09 BR BRPI0515033-7A patent/BRPI0515033B1/pt not_active IP Right Cessation
- 2005-09-09 PT PT10150124T patent/PT2177528E/pt unknown
- 2005-09-09 SI SI200531830T patent/SI2361924T1/sl unknown
- 2005-09-09 PL PL10150124T patent/PL2177528T3/pl unknown
- 2005-09-09 RS RS20140097A patent/RS53248B/sr unknown
- 2005-09-09 AU AU2005282249A patent/AU2005282249B2/en not_active Expired
- 2005-09-09 UA UAA200703838A patent/UA91029C2/uk unknown
- 2005-09-09 CA CA2579656A patent/CA2579656C/en not_active Expired - Lifetime
- 2005-09-09 WO PCT/US2005/032395 patent/WO2006029393A2/en not_active Ceased
2006
- 2006-09-27 US US11/529,668 patent/US20070021324A1/en not_active Abandoned
2007
- 2007-02-27 IL IL181596A patent/IL181596A/en active IP Right Grant
- 2007-03-16 IS IS8622A patent/IS8622A/is unknown
- 2007-03-28 NO NO20071632A patent/NO20071632L/no not_active Application Discontinuation
2010
- 2010-03-31 CY CY20101100308T patent/CY1110280T1/el unknown
2012
- 2012-03-02 HR HRP20120209TT patent/HRP20120209T1/hr unknown
2014
- 2014-03-10 HR HRP20140216TT patent/HRP20140216T1/hr unknown
2015
- 2015-09-17 IL IL241702A patent/IL241702A0/en unknown

Also Published As

Publication number	Publication date
DK2361924T3 (en)	2014-03-10
US20070021324A1 (en)	2007-01-25
EP2177528B1 (de)	2011-12-07
AU2005282249A1 (en)	2006-03-16
PL2361924T3 (pl)	2014-08-29
KR20070059137A (ko)	2007-06-11
WO2006029393A3 (en)	2007-12-13
CN101166754A (zh)	2008-04-23
WO2006029393A8 (en)	2007-04-19
ZA200702591B (en)	2009-03-25
ATE454396T1 (de)	2010-01-15
WO2006029393A2 (en)	2006-03-16
IS8622A (is)	2007-03-16
BRPI0515033A8 (pt)	2019-01-22
JP5149008B2 (ja)	2013-02-20
RS53248B (sr)	2014-08-29
HRP20100164T1 (hr)	2010-07-31
ES2451006T3 (es)	2014-03-26
HRP20140216T1 (hr)	2014-06-06
EP2361924B1 (de)	2013-12-11
EP1799703A2 (de)	2007-06-27
ES2338138T3 (es)	2010-05-04
MX2007002760A (es)	2007-05-18
JP2008512494A (ja)	2008-04-24
BRPI0515033B1 (pt)	2021-05-25
US7495072B2 (en)	2009-02-24
DE602005018800D1 (de)	2010-02-25
CN101166754B (zh)	2014-04-23
SI2361924T1 (sl)	2014-04-30
DK1799703T3 (da)	2010-04-19
SI1799703T1 (sl)	2010-04-30
KR101317131B1 (ko)	2013-10-10
US20060052586A1 (en)	2006-03-09
CA2579656A1 (en)	2006-03-16
NZ554018A (en)	2009-06-26
HK1140775A1 (en)	2010-10-22
EP2361924A1 (de)	2011-08-31
IL181596A (en)	2015-10-29
HK1156637A1 (en)	2012-06-15
EP2177528A1 (de)	2010-04-21
HK1100780A1 (en)	2007-09-28
IL241702A0 (en)	2015-11-30
DK2177528T3 (da)	2012-03-26
SI2177528T1 (sl)	2012-04-30
PT1799703E (pt)	2010-03-04
RU2007112956A (ru)	2008-10-20
CA2579656C (en)	2014-11-04
BRPI0515033A (pt)	2008-07-01
EP1799703B1 (de)	2010-01-06
EP1799703A4 (de)	2008-09-03
RS52265B (sr)	2012-10-31
RS51257B (sr)	2010-12-31
HRP20120209T1 (hr)	2012-06-30
RU2388764C2 (ru)	2010-05-10
PT2177528E (pt)	2012-03-19
ES2382298T3 (es)	2012-06-07
PL1799703T3 (pl)	2010-06-30
PL2177528T3 (pl)	2012-09-28
PT2361924E (pt)	2014-03-13
IL181596A0 (en)	2007-07-04
NO20071632L (no)	2007-06-05
CY1110280T1 (el)	2015-01-14
UA91029C2 (uk)	2010-06-25
AU2005282249B2 (en)	2012-08-02

Publication	Publication Date	Title
ATE536363T1 (de)	2011-12-15	Verfahren zur herstellung von mischungen von trifluoroacetyl-glatirameracetat bei verwendung von hydrobromsäure
DE60320362D1 (de)	2008-05-29	Verfahren zur Herstellung von Dipeptiden
DK1961811T3 (da)	2010-11-08	Cytokinligand til behandling af asthma og luftvejs-hyper-responsivitet
ATE462000T1 (de)	2010-04-15	Verfahren zur herstellung von l-arginin, l- ornithin oder l-citrullin
ATE368688T1 (de)	2007-08-15	Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
ATE154609T1 (de)	1997-07-15	Nicht-lineare peptide, die hydropatisch komplementär zu bekannten aminosäuresequenzen sind, verfahren zur herstellung und verwendung davon
DE602004028239D1 (de)	2010-09-02	Protease, für die protease codierende dna und verfahren zur herstellung der protease
ATE411281T1 (de)	2008-10-15	Verfahren zur herstellung von s-aryl-cystein
IL173954A0 (en)	2006-07-05	Libraries of recombinant chimeric proteins and methods of generating the same
ATE452903T1 (de)	2010-01-15	Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
ATE479745T1 (de)	2010-09-15	Nukleotidsequenzen codierend für deregulierte phosphoglycerat-dehydrogenasen coryneformer bakterien sowie verfahren zur herstellung von l- serin
ATE556135T1 (de)	2012-05-15	Neues protein
EP1467207A4 (de)	2006-06-07	Screening-verfahren
DE602005016857D1 (de)	2009-11-12	Verfahren zur Herstellung von Tripeptid-Zwischenprodukten zur Herstellung von LHRH-Antagonisten
CY1115096T1 (el)	2016-12-14	Διαδικασια για την παρασκευη μιγματων trifluoroacetyl glatiramer acetate χρησιμοποιωντας καθαρισμενο υδροβρωμικο οξυ
EP1566386A4 (de)	2006-06-07	Gen in zusammenhang mit haarausfall, das davon kodierte polypeptid und anwendungen dafür
ATE529437T1 (de)	2011-11-15	Verfahren zur sauerstoff-regulierten produktion von recombinanter staphylokinase